文献速递病毒性肝炎

美国慢性乙肝成人一次性普遍HDV检测的成本效果

Cost-Effectiveness of One-time Universal Testing for Hepatitis D Among Adults With Chronic Hepatitis B in the United States.
PubMed 文献 · Clin Infect Dis · 2025-01-01

该研究用Markov模型评估美国HBsAg阳性成人一次性普遍HDV抗体检测(阳性者再测HDV RNA)的成本效果。每10万筛查者中,普遍检测可避免100例HDV相关死亡、30例肝硬化和50例肝细胞癌,并增加1500个QALY。在5万美元/QALY支付阈值下,普遍检测联合PEG-IFN治疗可能具有成本效果。

要点

  • 美国仅约12.9%的CHB成人接受过HDV抗体检测。
  • 每10万HBsAg阳性者筛查,普遍检测可避免100例HDV相关死亡。
  • 在5万美元/QALY阈值下,普遍检测联合PEG-IFN治疗可能具有成本效果。

核心结论

  • 对美国所有HBsAg阳性成人进行一次性HDV检测,并对慢性HDV感染使用PEG-IFN治疗,可能具有成本效果。

研究设计与样本

  • 采用Markov模型计算美国HBsAg阳性成人普遍HDV检测的成本、健康影响和成本效果。
  • 假设50%的HDV RNA阳性患者接受当前推荐的PEG-IFN治疗48周,应答率为30%。
  • 还模拟了假设性无限期HDV抗病毒治疗(更高应答率)的影响,以评估具有成本效果的年度药物成本阈值。

主要发现

  • 每10万HBsAg阳性个体筛查,普遍HDV检测可避免100例HDV相关死亡、额外30例肝硬化和50例肝细胞癌。
  • 每10万HBsAg阳性个体筛查,普遍HDV检测可能带来1500个质量调整生命年(QALY)的增益。

临床怎么用

  • 研究结果支持对美国HBsAg阳性成人考虑一次性普遍HDV检测,并对慢性HDV感染使用PEG-IFN治疗,因其可能具有成本效果。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic hepatitis D virus (HDV) infection increases the risk of liver-related deaths in adults with chronic hepatitis B (CHB). In the United States (US), only an estimated 12.9% of adults with CHB have received an HDV antibody test. The aim of this study is to calculate the cost-effectiveness of one-time universal HDV testing of hepatitis B surface antigen (HBsAg)-positive adults living in the US. METHODS: A Markov model was used to calculate the costs, health impact, and cost-effectiveness of universal testing of HBsAg-positive adults with an HDV antibody test and, when positive, an HDV RNA test for chronic HDV infection. We assumed that 50% of the HDV RNA-positive patients would receive the current recommended treatment with pegylated interferon (PEG-IFN) for 48 weeks with a 30% response rate. We also modeled the potential impact of hypothetical indefinite HDV antiviral therapy with a higher response rate to assess the annual cost threshold to be considered cost-effective. RESULTS: Universal HDV testing of adults with CHB could avert 100 HDV-related deaths and an additional 30 cases of cirrhosis and 50 cases of hepatocellular carcinoma, and potentially result in a gain of 1500 quality-adjusted life-years (QALYs) per 100 000 HBsAg-positive individuals screened. At a willingness-to-pay threshold of $50 000 per QALY, the annual drug costs for a hypothetical indefinite therapy with a 50% or 70% treatment response rate would need to cost ≤$13 027 and ≤$14 104, respectively. CONCLUSIONS: One-time HDV testing for all HBsAg-positive adults and treatment of chronic HDV infection with PEG-IFN is potentially cost-effective in the US.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Toy M, Hutton D, Teshale E, et al. Cost-Effectiveness of One-time Universal Testing for Hepatitis D Among Adults With Chronic Hepatitis B in the United States. Clin Infect Dis. 2025. PMID: 40198094. doi:10.1093/cid/ciaf181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。